What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
His primary scientific interests are in Pathology, Internal medicine, Cardiology, Stent and Thrombosis.
His work focuses on many connections between Pathology and other disciplines, such as Thin-cap fibroatheroma, that overlap with his field of interest in Stenosis.
His research investigates the link between Internal medicine and topics such as Endocrinology that cross with problems in Thoracic aorta and Case-control study.
All of his Cardiology and Coronary artery disease, Coronary thrombosis, Myocardial infarction and Unstable angina investigations are sub-components of the entire Cardiology study.
In his research, Sirolimus, Fibrin, Neointima and Wound healing is intimately related to Paclitaxel, which falls under the overarching field of Stent.
His work deals with themes such as Thrombus and Sudden cardiac death, which intersect with Thrombosis.
His most cited work include:
- Lessons From Sudden Coronary Death A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions (3163 citations)
- Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk (2345 citations)
- Pathology of the Vulnerable Plaque (1698 citations)
What are the main themes of his work throughout his whole career to date?
Frank D. Kolodgie mainly investigates Internal medicine, Cardiology, Pathology, Stent and Surgery.
His Internal medicine study frequently draws connections to adjacent fields such as Endocrinology.
Many of his studies on Cardiology involve topics that are commonly interrelated, such as Autopsy.
His Pathology study incorporates themes from Inflammation and Apoptosis.
The study incorporates disciplines such as Sirolimus and Urology in addition to Stent.
Frank D. Kolodgie has researched Restenosis in several fields, including Artery and Percutaneous coronary intervention.
He most often published in these fields:
- Internal medicine (37.18%)
- Cardiology (29.18%)
- Pathology (27.53%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (37.18%)
- Cardiology (29.18%)
- Stent (22.82%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cardiology, Stent, Surgery and Pathology are his primary areas of study.
His work on Internal medicine is being expanded to include thematically relevant topics such as Histopathology.
His Cardiology study frequently draws connections to other fields, such as Autopsy.
His research integrates issues of Thrombogenicity, Ex vivo, Everolimus and Urology in his study of Stent.
His study in Surgery is interdisciplinary in nature, drawing from both Clinical trial and Pharmacology.
He interconnects Inflammation, Coronary arteries and Coronary atherosclerosis in the investigation of issues within Pathology.
Between 2015 and 2021, his most popular works were:
- Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis (225 citations)
- Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis (92 citations)
- CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis (83 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Frank D. Kolodgie mainly focuses on Stent, Pathology, Internal medicine, Cardiology and Thrombogenicity.
Stent is a subfield of Surgery that Frank D. Kolodgie investigates.
His Pathology research includes elements of Coronary artery disease, Extracellular matrix and Stage.
Internal medicine is frequently linked to Endocrinology in his study.
His Cardiology study frequently draws connections between adjacent fields such as Angiotensin II.
His research in Thrombogenicity focuses on subjects like Thrombus, which are connected to Aortic valve replacement, Implant, Thrombosis and Valve replacement.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
